What is it about?
Summarizes current evidence regarding the use of oral vancomycin as a secondary prophylactic strategy in patients being treated with antibiotics not targeting Clostridium difficile. Due to the absence of prospective evidence demonstrating long term safety and efficacy of secondary prophylaxis, this review also reflects on potential consequences of this strategy that should be taken into consideration by clinicians.
Featured Image
Why is it important?
Clostridium difficile infections remain a major burden on healthcare systems and patients worldwide despite widespread adoption of infection control practices geared towards prevention. Recurrent C. difficile infections carry an even greater cost and strategies to prevent recurrence in patients being exposed to antibiotics should be explored.
Perspectives
In depth look at a strategy that is being increasingly utilized to prevent recurrent C. difficile infections that lacks prospective evidence of safety and efficacy.
Chase Brown
Medical University of South Carolina
Read the Original
This page is a summary of: Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection, Annals of Pharmacotherapy, November 2018, SAGE Publications,
DOI: 10.1177/1060028018815170.
You can read the full text:
Contributors
The following have contributed to this page
